CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Choosing the right rewards program can significantly impact your benefits. Learn which one suits you best.
27,692 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Walmart isn't biggest company anymore, but its growth story isn t over. A new catalyst—driving e commerce, membership...
U.S. lenders are accelerating cash returns to shareholders after stress tests and capital rules ease. JPMorgan, Bank ...
Chipotle and Microsoft have taken divergent paths in 2026. CMG rides restaurant-demand strength while MSFT grapples w...
United Wholesale Mortgage announces a free 1-0 temporary rate buydown on purchase loans and introduces a new home equ...
AI networking is redefining data centers, and Arista Networks sits at the center of that shift. This article explains...
Vitalik selling ethereum grabs attention in a thin market, but the bigger signal may be the Ethereum Foundation's mov...
A major fund is doubling down on Lionsgate Studios as shares skyrocket. Learn what know about this bet, the strategy ...
Playnance’s G Coin started trading on MEXC following its Token Generation Event, unleashing a dramatic early surge in...
GCOIN makes its WEEX debut as part of a broader plan to list on five exchanges this June, signaling a major push to w...
Two industry giants released mixed Q1 results, highlighting divergent paths for July. Lockheed Martin stays mission-f...
Lawmakers unveil the Senior Citizens' Freedom to Work Act, which would end the retirement earnings test and let retir...